Fast, simple, and reliable fibrinogen replacement
Biotest is delighted to announce that the new human fibrinogen Prufibry® has been approved by the German competent authority, the Paul-Ehrlich-Institute, for the German market
- for the treatment and perioperative prophylaxis of bleeding in patients with congenital hypo- or afibrinogenemia with bleeding tendency,
- as a complementary therapy to management of uncontrolled severe haemorrhage in acquired hypofibrinogenemia caused by surgery or trauma.
The approval represents another important milestone in Biotest’s strategy to broaden its portfolio in the fields of intensive care and coagulation disorders and to strengthen supply security for patients worldwide. As CEO Dr. Jörg Schüttrumpf said: “With this approval, patients suffering from congenital and acquired fibrinogen deficiency will gain access to an effective and safe therapy to prevent and control life-threatening bleeding events especially in surgical and trauma settings.”
Prufibry® is a highly purified product with a precisely defined amount of fibrinogen, enabling a targeted dosage and a rapid replenishment of fibrinogen levels, which is important in critical moments.
Prufibry® is produced in the new “Biotest Next Level” production facility in Dreieich, Germany. This state-of-the-art manufacturing platform reflects Biotest's high standards of quality, safety and innovation in plasma-based therapies.
Biotest is pleased to announce that Prufibry® will soon be available to physicians and patients in Germany.